11.10

6.41% -0.76

Neogenomics Inc (NEO)

Overview News Price History Option Chain Financials Why NEO Down? Discussions Forecast Stock Split

Neogenomics Inc stock is traded at $11.10, with a volume of 1.84M. It is down -6.41% in the last 24 hours and down -21.72% over the past month. NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Previous Close:

$11.86

Open:

$12.03

24h Volume:

1.84M

Relative Volume:

2.18

Market Cap:

$1.43B

Revenue:

$628.25M

Net Income/Loss:

$-78.55M

P/E Ratio:

-17.90

EPS:

-0.62

Net Cash Flow:

$-29.73M

1W Performance:

-23.02%

1M Performance:

-21.72%

6M Performance:

-32.44%

1Y Performance:

-32.65%

1-Day Range:

$10.90

$12.03

1-Week Range:

$10.69

$13.30

52-Week Range:

$10.69

$19.11

Neogenomics Inc Stock (NEO) Company Profile

Name

Neogenomics Inc

Sector

Healthcare (1169)

Industry

Diagnostics & Research (60)

Phone

(239) 768-0600

Address

9490 NEOGENOMICS WAY, FORT MYERS, FL

Employee

2,200

Twitter

@NeoGenomics

Next Earnings Date

2025-02-18

Latest SEC Filings

NEO's Discussions on Twitter

Compare NEO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NEO Neogenomics Inc	11.10	1.43B	628.25M	-78.55M	-29.73M	-0.62
TMO Thermo Fisher Scientific Inc	532.55	203.70B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	210.23	151.18B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	135.37	38.62B	6.51B	1.29B	1.37B	4.42
IDXX Idexx Laboratories Inc	452.77	37.07B	3.90B	887.87M	808.08M	10.67
IQV Iqvia Holdings Inc	191.04	33.64B	15.41B	1.37B	2.11B	7.50

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-13-25	Downgrade	The Benchmark Company	Buy → Hold
Dec-10-24	Initiated	Jefferies	Buy
May-01-24	Resumed	Craig Hallum	Buy
Dec-29-23	Reiterated	BTIG Research	Buy
Aug-21-23	Upgrade	Stephens	Equal-Weight → Overweight
May-16-23	Downgrade	Raymond James	Outperform → Mkt Perform
May-09-23	Upgrade	BTIG Research	Neutral → Buy
Feb-24-23	Upgrade	The Benchmark Company	Hold → Buy
Feb-01-23	Upgrade	Needham	Hold → Buy
Aug-26-22	Downgrade	The Benchmark Company	Buy → Hold
Aug-22-22	Downgrade	Needham	Buy → Hold
Jun-03-22	Initiated	Piper Sandler	Overweight
Mar-29-22	Downgrade	BofA Securities	Buy → Neutral
Mar-29-22	Downgrade	Stephens	Overweight → Equal-Weight
Jan-18-22	Resumed	Stephens	Overweight
Dec-16-21	Initiated	Cowen	Outperform
Nov-05-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-14-21	Upgrade	Raymond James	Mkt Perform → Outperform
Jun-03-21	Initiated	Goldman	Buy
Feb-25-21	Resumed	Needham	Buy
Feb-25-21	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-28-21	Initiated	Truist	Buy
Dec-11-20	Resumed	BTIG Research	Buy
Oct-28-20	Reiterated	Needham	Buy
Sep-09-20	Initiated	Morgan Stanley	Overweight
Aug-28-20	Initiated	Guggenheim	Buy
Jul-29-20	Reiterated	Needham	Buy
Jun-25-20	Initiated	BofA/Merrill	Buy
Apr-21-20	Resumed	Stephens	Overweight
Mar-02-20	Resumed	Craig Hallum	Buy
Feb-28-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Jan-23-20	Downgrade	First Analysis Sec	Strong Buy → Outperform
Oct-30-19	Reiterated	Needham	Buy
May-01-19	Reiterated	Needham	Buy
Mar-29-19	Reiterated	Needham	Buy
Jan-03-19	Initiated	Needham	Buy
Oct-24-18	Upgrade	First Analysis Sec	Outperform → Strong Buy
Aug-21-18	Initiated	Leerink Partners	Outperform
May-02-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
Sep-11-17	Downgrade	BTIG Research	Buy → Neutral
Aug-24-17	Initiated	Gabelli & Co	Buy
Dec-15-16	Initiated	Cantor Fitzgerald	Overweight

View All

Neogenomics Inc Stock (NEO) Latest News

Feb 21, 2025

NeoGenomics plummets on Q4 2024 bottom line miss, soft EPS guidance - MSN

Feb 21, 2025

Feb 20, 2025

Bank of America Issues Pessimistic Forecast for NeoGenomics (NASDAQ:NEO) Stock Price - MarketBeat

Feb 20, 2025

NeoGenomics (NASDAQ:NEO) Price Target Cut to $18.00 by Analysts at Needham & Company LLC - MarketBeat

Feb 20, 2025

Feb 19, 2025

NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021 - ACCESS Newswire

Feb 19, 2025

BTIG cuts Neogenomics price target to $17, maintains Buy rating - Investing.com India

Feb 19, 2025

BTIG cuts Neogenomics price target to $17, maintains Buy rating By Investing.com - Investing.com Canada

Feb 19, 2025

NeoGenomics, Inc. (NASDAQ:NEO) Q4 2024 Earnings Call Transcript - MSN

Feb 19, 2025

NeoGenomics (NASDAQ:NEO) Sets New 52-Week Low After Earnings Miss - MarketBeat

Feb 19, 2025

Morgan Stanley cuts Neogenomics stock target to $17 from $18 By Investing.com - Investing.com Canada

Feb 19, 2025

NeoGenomics (NASDAQ:NEO) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS - MarketBeat

Feb 19, 2025

NeoGenomics price target lowered to $19 from $20 at TD Cowen - TipRanks

Feb 19, 2025

NeoGenomics (NASDAQ:NEO) Issues Earnings Results - MarketBeat

Feb 19, 2025

NeoGenomics targets 1M patients annually by 2028 with 11%-13% revenue growth in 2025 - MSN

Feb 19, 2025